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Objective Hyperkalemia affects up to 10% of hospitalized patients and, if left untreated, can 
lead to serious cardiac arrhythmias or death. Although hyperkalemia is frequently encountered 
in the emergency department (ED), and is potentially life-threatening, standard of care for the 
treatment is poorly defined, with little supporting evidence. The main objectives of this observa-
tional study are to define the overall burden of hyperkalemia in the ED setting, describe its 
causes, the variability in treatment patterns and characterize the effectiveness and safety of ED 
standard of care therapies used in the United States. 
Methods This is an observational study evaluating the management of hyperkalemia in the ED. 
Two hundred and three patients who presented to the ED with a potassium value ≥5.5 mmol/L 
were enrolled in the study at 14 sites across the United States. Patients were treated per stan-
dard of care  practices at the discretion of the patient’s physician. In patients who received a 
treatment for hyperkalemia, blood samples were drawn at pre-specified time points and serum 
potassium values were recorded. The change in potassium over 4 hours and the adverse events 
after standard of care treatment were analyzed. 
Results and Conclusion This article describes the background, rationale, study design, and meth-
odology of the REVEAL-ED (Real World Evidence for Treatment of Hyperkalemia in the Emergen-
cy Department) trial, a multicenter, prospective, observational study evaluating contemporary 
management of patients admitted to the ED with hyperkalemia.
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INTRODUCTION 
Hyperkalemia occurs in up to 10% of hospitalized patients.1-4 Pa-
tients with chronic kidney disease and cardiovascular disease, as 
well as those who are treated with renin-angiotensin-aldosterone 
system inhibitors, are at greater risk of hyperkalemia.5,6 The prev-
alence of hyperkalemia and related hospitalizations are on the 
rise in parallel with increased use of renin-angiotensin-aldoste-
rone system inhibitors and an aging hospitalized patient popula-
tion.7 Patients are often sent to the emergency department (ED) 
due to high potassium levels, and over 800,000 hyperkalemia-re-
lated ED visits are estimated to occur annually in the US.8 
 If left untreated, hyperkalemia can lead to life-threatening car-
diac arrhythmias,9-11 and is associated with substantially increased 
risk of death.12-14 One study reported in-hospital mortality of pa-
tients with hyperkalemia to be as high as 18.1%, while those with 
normal potassium to be 3.9%.13 Several other studies have also 
shown an increase in the risk of death for serum potassium levels 
above 5 mmol/L and a rapid increase in the risk of death as serum 
potassium levels exceed 5.5 mmol/L.6,14,15 In particular, a study by 
Grodzinsky el al.15 reported that in-hospital mortality was greater 
than 15% once the maximum potassium level was above 5.5 mmol/L, 
and another study by Einhorn et al.6 reported a 1-day mortality 
rate up to 17 times higher for hospitalized patients with potassi-
um levels >6.0, as compared to <5.5 mmol/L. 
 Although no randomized trials on hyperkalemia treatments 
and their impact on in-hospital mortality have been conducted, 
available observational data suggest that reducing potassium lev-
els in patients with hyperkalemia may lower mortality risk. For 
example, an observational cohort study at two medical centers in 
Korea found that treatment of patients with hyperkalemia with 
common therapies excluding dialysis, improved serum potassium 
levels and had a positive association with better survival.16 A sep-
arate observational study of hospitalized patients who received 
critical care at two tertiary care hospitals in Boston, MA, showed 
that a reduction of 1 mmol/L or greater in serum potassium with-
in 48 hours after hospitalization was associated with decreased 
mortality risk.17 In addition, a retrospective study of 38,689 con-
secutive patients with acute myocardial infarction found that in-
hospital mortality was twice as high among hyperkalemic patients 
whose potassium levels remained high compared to patients whose 
potassium levels returned to a normal range.15 
 Although hyperkalemia is frequently encountered in the ED, 
and is potentially life-threatening, a standard of care (SOC) for 
hyperkalemia treatment is poorly defined. Acute pharmacologic 
treatment options for hyperkalemia are limited and their use is 
complicated by suboptimal tolerability and safety and uncertain 
efficacy. Hemodialysis is effective for the treatment of hyperkale-
mia, but is invasive and costly, and significant logistical issues 
must be overcome in order to initiate this in the ED. In addition, 
the emergency management of hyperkalemia is not consistent 
across clinicians and institutions in the US.18 A Cochrane review 
of emergency management of hyperkalemia suggested that suf-
ficient randomized, controlled trials supporting the use of com-
monly prescribed therapies are lacking and many of the trials are 
methodologically flawed.18 Accordingly, we conducted a multi-
center, prospective, observational study to define the overall bur-
den of hyperkalemia in the ED setting, describe its causes, and 
variability in treatment patterns and characterize the effective-
ness and safety of ED SOC therapies used in the US. We hypothe-
sized that SOC treatment of hyperkalemia is variable and multiple 
medications are used in the acute setting. We further hypothe-
sized that all SOC medications are effective in the first four hours 
of treatment. To our knowledge, this is the first prospective, rigor-
ously designed observational study directly addressing gaps in 
knowledge in the US.
METHODS
Study design 
The Real World Evidence for Treatment of Hyperkalemia in the 
Emergency Department (REVEAL-ED) is a multicenter, prospec-
What is already known
Hyperkalemia is frequently encountered in the emergency department and is potentially life threatening. Standard-of-
care treatment for hyperkalemia is limited and poorly defined.
What is new in the current study
This is the first prospective, observational study addressing gaps in knowledge in hyperkalemia treatment. This article 
describes the background, rational and methodology of the REVEAL-ED (Real World Evidence for Treatment of Hyper-
kalemia in the Emergency Department) trial.
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tive, observational study evaluating the management of patients 
admitted to the ED with hyperkalemia. The study was approved 
by the institutional review board or local ethics committee for 
each site and registered at ClinicalTrials.gov (NCT02607085). Each 
patient, legally authorized guardian, or a person with legal re-
sponsibility for the patient’s health care decisions provided writ-
ten informed consent prior to participation in any study activities.
Study setting and population
From October 25, 2015 to March 30, 2016, a total of 203 patients 
who presented to the ED with a potassium value ≥5.5 mmol/L 
were enrolled in the study at 14 sites across the US (Fig. 1). Eligi-
ble patients were ≥18 years of age, provided written informed 
consent, and had hyperkalemia confirmed in the ED with a docu-
mented potassium ≥5.5 mmol/L. Enrollment of patients with a 
baseline potassium <6.0 mmol/L was limited to 50 patients, after 
which the entry criteria required a baseline potassium ≥6.0 mmol/L. 
A point-of-care analyzer was allowed to determine the baseline 
potassium level if this was the standard practice at that site. Pa-
tients were excluded from the study if, in the opinion of the treat-
ing physician, they were unable to perform the tasks associated 
with the protocol, they were participating in another clinical study 
which could impact the REVEAL-ED study or they had been previ-
ously enrolled in this study. 
Study protocol
After patients provided written informed consent, their demo-
graphics and medical history data, including previous ED visits 
and hospital admissions for hyperkalemia, were recorded. Patients 
with a prior history of heart failure were classified according to 
the New York Heart Association functional classification system. 
 The baseline study-related whole blood potassium was deter-
Fig. 1. REVEAL-ED (Real World Evidence for Treatment of Hyperkalemia 
in the Emergency Department) study sites. Marked areas on the map 
represent study sites in the US.
mined using a point-of-care device (i-STAT; Abbott Point of Care, 
Princeton, NJ, USA), provided by the sponsor, prior to the first in-
tervention for hyperkalemia. If no baseline study-related potassi-
um value was obtained, then the potassium value qualifying the 
patient for study entry was considered as the patient’s baseline. If 
the SOC potassium value qualifying the patient for the study was 
≥5.5 mmol/L, but the baseline i-STAT value was <5.5 mmol/L 
then the SOC value was recorded and the patient was allowed to 
remain in the study.
 In patients who received a treatment for hyperkalemia, study-
related potassium samples were drawn and analyzed by i-STAT at 
0.5, 1, 2, 4, 8, 12, and 24 hours after intervention initiation (Fig. 
2). If a patient was transferred from the ED to another hospital 
location, then research staff continued to collect study-related i-
STAT samples to the extent feasible. If a patient received more 
than one intervention for hyperkalemia, then the post-treatment 
potassium measurement schedule started from the initiation of 
the first intervention, except if a patient received sodium polysty-
rene sulfonate, then additional study-related potassium samples 
were drawn at 1, 2, and 4 hours following initial sodium polysty-
rene sulfonate administration. 
 In patients who received no intervention during the initial 4-hour 
period, study-related potassium samples were drawn and ana-
lyzed by i-STAT at 4, 8, 12, and 24 hours after the SOC potassium 
measurement qualifying the patient for study entry. If a patient 
was transferred from the ED to another hospital location, then 
the site continued to collect study-related i-STAT samples to the 
extent feasible. 
 Patients were treated per SOC practices at the discretion of the 
patient’s physician. Any medication administered as part of SOC 
practice was provided according to the drug dispensing policy at 
each investigational site. No specific treatment algorithms were 
prescribed by the study protocol, and no medications were sup-
plied by the sponsor during the study. Available data obtained as 
part of ED SOC management were recorded upon ED admission 
and up to 24 hours after the initial intervention, or through 24 
Fig. 2. Study design.     
Screening: (1) Standard of care potassium, (2) subject’s chief complaints 
upon arrival at emergency department, (3) assess possible cause of hyper-
kalemia, and (4) New York Heart Association assessment if history of heart 
failure.
Initial intervention/treatment
Blood draws to measure potassium levels
Concomitant medications assessment
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hours after the potassium measurement that qualified the patient 
for entry into the study if no intervention was performed. Avail-
able SOC management data that was recorded included physical 
examinations, vital signs, fluid intake and urine output, electro-
cardiograms, clinical laboratory data, and results of chest X-rays. 
Data regarding the patient’s chief complaint upon ED admission, 
possible cause of the patient’s hyperkalemia, as well as admitting 
and discharge diagnoses were recorded. The patient’s overall dis-
charge summary and hospital discharge time were also collected 
when possible.
 The timing of each hyperkalemia intervention following ED ad-
mission as well as the dose and route of administration were re-
corded. Concomitant medications were collected for the 14 days 
before ED admission through ED discharge. If a patient was admit-
ted to another hospital location (i.e., to an in-patient bed), medica-
tions administered after ED evaluation was collected for up to sev-
en days or until discharge from the hospital, whichever came first. 
 Dates and times were recorded for the following (if applicable): 
ED admission, hospital admission, intensive care unit admission, 
observation unit admission, step down unit admission, regular 
floor admission, discharge (from all admissions), dialysis, do not 
resuscitate order entry, death, and any other recordable outcome 
deemed significant by the investigator. 
 Recordable outcomes were limited to pulmonary edema, ven-
tricular tachycardia/fibrillation, pulseless electrical activity arrest, 
new clinically significant electrocardiogram changes (specifically 
including but not limited to severe bradycardia, advanced heart 
block, bundle branch block, tachycardia [>100 bpm]), palpitations, 
hypoglycemia, and gastrointestinal-related events (e.g., nausea, 
vomiting, diarrhea) and any other event deemed significant by 
the investigator. Recordable outcomes requiring positive-pressure 
ventilation, central venous access, intubation, chest compressions, 
intravenous (IV) vasopressors, IV vasodilators, IV anti-arrhythmics, 
and/or emergency dialysis or resulting in death were also collect-
ed. These outcomes were recorded from the time of ED admission 
through ED discharge. If a patient was admitted to another hos-
pital location, post-ED recordable outcomes were collected for up 
to 7 days following admission to that unit or until hospital dis-
charge, if earlier. Recordable outcomes resulting in death while the 
patient remained in the hospital were collected for up to 30 days 
after ED admission. 
Outcome measures 
The primary endpoint of the study was the absolute change in 
potassium over 4 hours following the initial intervention for hy-
perkalemia. If a patient did not receive an intervention for hyper-
kalemia during the ED admission, then the change over 4 hours 
following the baseline potassium measurement was used. 
 Secondary endpoints included the rate of change in potassium 
over 4 hours following the initial intervention for hyperkalemia, 
change in potassium at other time points (rate, percent and ab-
solute), choice of intervention, timing and details of procedures 
relative to ED admission, other outcome events (e.g., hospital and 
intensive care unit admissions, cardiac arrhythmias and conduc-
tion abnormalities, hemodynamic instability/cardiac arrest, in-
hospital deaths), as well as safety and tolerability of SOC inter-
ventions were also evaluated. 
Data analysis 
No formal sample size calculation was performed for this study. A 
sample size of 200 patients was selected based on clinical judge-
ment and was considered sufficient to adequately characterize 
the different interventions in this population. The study popula-
tions for analysis include the intent-to-treat and safety popula-
tions. The intent-to-treat population included all patients enrolled 
in the study with any post-baseline study-related potassium val-
ues. The safety population included all patients enrolled in the 
study who had any post-baseline follow-up for safety. 
 Changes in study-related potassium values following an inter-
vention were used to assess efficacy. All analyses were based on 
the study-related potassium results obtained using i-STAT. Safety 
was evaluated using recordable outcomes, clinical laboratory pa-
rameters, vital signs, fluid intake and urine output, physical ex-
amination, electrocardiograms, and chest X-rays. The principle of 
treatment emergence was employed for the analysis of record-
able outcome data. Treatment emergence was defined to be any 
event that occurred during the observation period of the study 
and was not present at baseline, or one that represents an exac-
erbation of a condition present at baseline. 
 Recordable outcomes were classified by the medical dictionary 
for regulatory activities (MedDRA). The type, incidence, timing 
(onset and duration), relationship to hyperkalemia and to inter-
vention for hyperkalemia, and severity of recordable outcome was 
reported for treatment-emergent outcomes. Reasons for withdra-
wal due to recordable outcomes were also reported. The incidence 
of clinically significant cardiac events (e.g., cardiac arrhythmia, 
cardiac arrest, cardiovascular and all-cause death) was calculat-
ed. All cardiac events were adjudicated by an independent review 
committee prior to database lock using available SOC data for 
each case. Descriptive statistics will be presented overall for the 
study population, as well as stratified by potassium levels at base-
line, and by treatment group. When appropriate, hierarchical mul-
tivariable analyses will be performed adjusting for differences in 
patient characteristics and hospital site.
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Role of the sponsor
The study sponsor participated in developing the study design, 
conducted data collection, and will participate in data analyses. 
The study investigators and all authors provided critical input for 
the study design and methodology, will have free access to the 
study data, will lead the analysis and interpretation of the data, 
and have sole discretion in the writing of the report and the deci-
sion to submit the manuscript for publication. 
DISCUSSION 
Hyperkalemia is frequently encountered in the ED and can lead to 
cardiac arrhythmias or death. Emergency management of hyper-
kalemia and close monitoring in the hospital setting is often nec-
essary, but SOC for hyperkalemia has not been well characterized. 
To our knowledge, this is the first prospective, rigorously designed 
observational study directly addressing the gaps in knowledge of 
hyperkalemia management in the United States.
 A few noteworthy points about our methodology are as follows: 
First, our primary end point is to measure the effect of an emer-
gent intervention in the first 4 hours. This time-line was chosen 
to evaluate how quickly the SOC intervention is effective, as se-
vere hyperkalemia can be lethal and quick interventions are need-
ed in the emergency setting. Moreover, this time frame made the 
study feasible to conduct in the ED setting. Second, we enrolled 
only fifty patients with a potassium range ≥5.5 mmol/L and <6.0 
mmol/L because we wanted to see the effectiveness of the inter-
ventions at higher potassium levels. Lastly, even though this was 
an ED based study and we were interested in the effectiveness of 
interventions in the first 4 hours, we collected data up to 7 days 
after admission, when applicable, so we could evaluate some of 
the lasting side effects of the SOC interventions. 
 This study has several limitations inherent to the nature of an 
observational study design. For instance, patients were not ran-
domized to the different interventions since they were treated per 
SOC practices at the discretion of the patient’s physician. Also, 
the medications administered as part of SOC practice were not 
standardized across investigational sites as medications were pro-
vided according to the hospital standards at each investigational 
site. Hence, we expect to find different dosages of the same med-
ication being used at different sites. The observational design of 
the study allows for an accurate description of the current SOC 
therapies used to treat hyperkalemia in the US, but the study is 
not designed to directly compare the efficacy of these interven-
tions.
 In summary, the REVEAL-ED study seeks to define the overall 
burden of hyperkalemia in the ED setting and will describe the 
variability in treatment patterns as well as characterize the effec-
tiveness and safety of ED SOC therapies used to treat hyperkale-
mia in the US.
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